Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) officer Christopher Ryan Sullivan has filed a notice under Rule 144 indicating an intent to sell up to 31,031 shares of common stock through Morgan Stanley Smith Barney. The shares relate to option exercises under a registered plan, including blocks of 25,124 and 5,907 shares for services rendered, with a proposed sale date of 08/18/2026. In the prior three months, Sullivan sold 3,749 shares for proceeds of $74,762.10.

Key Figures

Shares proposed for sale: 31,031 shares Option-related block 1: 25,124 shares Option-related block 2: 5,907 shares +4 more

7 metrics

Shares proposed for sale 31,031 shares Maximum AVTX common shares indicated for sale under Rule 144

Option-related block 1 25,124 shares Common shares from Exercise of Options Under a Registered Plan for services rendered

Option-related block 2 5,907 shares Additional common shares from Exercise of Options Under a Registered Plan for services rendered

Recent shares sold 3,749 shares AVTX common shares sold on 08/17/2026

Proceeds from recent sale $74,762.10 Total consideration for 3,749 AVTX shares sold on 08/17/2026

Broker-dealer firm code 31031 Code associated with Morgan Stanley Smith Barney LLC Executive Financial Services

Proposed sale date 08/18/2026 Date listed for the Rule 144 sale of AVTX common shares

Key Terms

Rule 144, Exercise of Options Under a Registered Plan, services rendered, Executive Financial Services

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Options Under a Registered Plan financial

"Common | 08/18/2026 | Exercise of Options Under a Registered Plan | Issuer"

services rendered financial

"25124 | 08/18/2026 | Services Rendered Common | 08/18/2026"

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What does the Form 144 filing disclose for Avalo Therapeutics (AVTX)?

The filing discloses that officer Christopher Ryan Sullivan plans to sell up to 31,031 AVTX common shares under Rule 144 through Morgan Stanley Smith Barney, with the proposed sale date of 08/18/2026 and shares tied to option exercises.

How many Avalo Therapeutics (AVTX) shares is Christopher Ryan Sullivan planning to sell?

Christopher Ryan Sullivan has noticed a potential sale of up to 31,031 AVTX common shares. This total comes from option-related blocks of 25,124 shares and 5,907 shares, all connected to services rendered and option exercises under a registered plan.

What recent AVTX stock sales has Christopher Ryan Sullivan reported before this Form 144?

In the past three months, Christopher Ryan Sullivan reported selling 3,749 AVTX common shares on 08/17/2026 for total proceeds of $74,762.10. This historical sale is separate from the newly noticed potential sale of up to 31,031 shares.

What is the nature of the Avalo Therapeutics (AVTX) shares covered by this Form 144?

The shares are common stock of Avalo Therapeutics (AVTX) obtained via Exercise of Options Under a Registered Plan. The filing states that the option-related shares, tied to services rendered, may be sold under Rule 144 through a brokerage firm.

Which broker is handling the potential sale of Avalo Therapeutics (AVTX) shares?

The potential sale of AVTX shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The shares are identified as Avalo Therapeutics common stock traded on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:19 PM Accepted by SEC EDGAR 08/18/2026 - 04:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001810417
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AVALO THERAPEUTICS, INC.
SEC File Number	001-37590
Address of Issuer	1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PENNSYLVANIA 19087
Phone	410-522-8707
Name of Person for Whose Account the Securities are To Be Sold	CHRISTOPHER RYAN SULLIVAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	31031	622221.20	53630000	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2026	Exercise of Options Under a Registered Plan	Issuer			25124	08/18/2026	Services Rendered
Common	08/18/2026	Exercise of Options Under a Registered Plan	Issuer			5907	08/18/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHRISTOPHER RYAN SULLIVAN 1500 Liberty Ridge Drive Suite 321 Wayne PA 19087	Common	08/17/2026	3749	74762.10

144: Remarks and Signature

Remarks
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christopher Ryan Sullivan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)